中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 3
Mar.  2023
Turn off MathJax
Article Contents

Value of liver-muscle signal intensity and serum markers in diagnosis of chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2023.03.014
Research funding:

Science and Technology Research and Development Project of Yan'an (2018KS-11)

More Information
  • Corresponding author: HUANG Xiaoqi, 344653354@qq.com (ORCID: 0000-0003-1365-759X)
  • Received Date: 2022-08-01
  • Accepted Date: 2022-09-06
  • Published Date: 2023-03-20
  •   Objective  To investigate the value of liver/muscle ratio (LMR) on susceptibility-weighted imaging (SWI) and serum markers in the diagnosis of the severity of chronic hepatitis B liver fibrosis after grouping based on alanine aminotransferase (ALT) level.  Methods  A retrospective analysis was performed for 255 patients with chronic hepatitis B who attended Affiliated Hospital of Yan'an University from October 2018 to September 2021, and the patients were divided into severe liver fibrosis group (SLF group) and non-severe liver fibrosis group (non-SLF group). The SLF group was defined as liver stiffness measurement (LSM) > 9.0 kPa and ALT level within the normal range or LSM > 12.0 kPa and ALT level greater than 1-5 times of the upper limit of normal. LMR was calculated by measuring the mean SWI value of the liver (SWIliver) and the signal intensity of the erector spinae. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two group; the chi-square test was used for comparison of categorical data between two groups. The binary logistic regression analysis was used to investigate the influencing factors for SLF. The receiver operating characteristic (ROC) curve was used to analyze the diagnostic performance of LMR and its combination with serum markers, and the DeLong test was used to compare the difference in the area under the ROC curve (AUC).  Results  Compared with the non-SLF group, the SLF group had significantly higher ALT (Z=-3.569, P < 0.001), aspartate aminotransferase (AST) (Z=-5.495, P < 0.001), hyaluronic acid (HA) (Z=-6.746, P < 0.001), laminin (LN) (Z=-5.459, P < 0.001), type Ⅳ collagen (Ⅳ-C)(Z=-8.470, P < 0.001), type Ⅲ procollagen (PCⅢ) (Z=-6.326, P < 0.001), aspartate aminotransferase-to-platelet ratio index (Z=-9.004, P < 0.001), and FIB-4 (Z=-8.357, P < 0.001) and significantly lower prothrombin time activity (PTA) (t=10.088, P < 0.001), platelet count (t=9.163, P < 0.001), SWIliver (t=2.347, P=0.02), and LMR×10 (Z=-4.447, P < 0.001). PTA, HA, Ⅳ-C, and LMR×10 were independent influencing factors for SLF. LMR×10 had an AUC of 0.675 (95% confidence interval [CI]: 0.614-0.732) in the diagnosis of SLF, which was significantly higher than that of SWIliver (AUC=0.594, 95%CI: 0.531-0.655) (Z=3.984, P < 0.001). PTA+HA+Ⅳ-C+LMR×10 and PTA+HA+Ⅳ-C had an AUC of 0.937 (95%CI: 0.896-0.966) and 0.905 (95%CI: 0.858-0.941), respectively, suggesting that PTA+HA+Ⅳ-C+LMR×10 had a better diagnostic performance than PTA+HA+Ⅳ-C (Z=2.228, P=0.026).  Conclusion  LMR and serum markers can accurately distinguish SLF after grouping based on ALT level. LMR is a quantitative and objective imaging indicator and is better than SWIliver, and it can also improve the diagnostic performance of serum markers for SLF in clinical practice.

     

  • loading
  • [1]
    Chinese Society of Infectious Diseases, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [2]
    SHIHA G, IBRAHIM A, HELMY A, et al. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update[J]. Hepatol Int, 2017, 11(1): 1-30. DOI: 10.1007/s12072-016-9760-3.
    [3]
    Chinese Society of Hepatology, Chinese Society of Gastroenterology, Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
    [4]
    European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1): 237-264. DOI: 10.1016/j.jhep.2015.04.006.
    [5]
    WANG L, ZHU M, CAO L, et al. Liver stiffness measurement can reflect the active liver necroinflammation in population with chronic liver disease: a real-world evidence study[J]. J Clin Transl Hepatol, 2019, 7(4): 313-321. DOI: 10.14218/JCTH.2019.00040.
    [6]
    HUANG LL, YU XP, LI JL, et al. Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection[J]. World J Gastroenterol, 2021, 27(7): 641-653. DOI: 10.3748/wjg.v27.i7.641.
    [7]
    SETO WK, HUI R, MAK LY, et al. Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2018, 16(4): 575-583.e2. DOI: 10.1016/j.cgh.2017.09.044.
    [8]
    CHENG Y, GUO R, LIU MG, et al. Value of MRI and quantitative serological markers detection to the diagnosis of liver fibrosis[J]. J Chin Pract Diagn Ther, 2018, 32 (6): 589-593. DOI: 10.13507/j.ssn.1674-3474.2018.06.021.

    程渝, 郭锐, 刘明国, 等. MRI与血清学定量指标检测对肝纤维化的诊断价值[J]. 中华实用诊断与治疗杂志, 2018, 32(6): 589-593. DOI: 10.13507/j.issn.1674-3474.2018.06.021.
    [9]
    Chinese Society of Infectious Diseases, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [10]
    CHENG DY, LI B, JI SJ, et al. Application of transient elastography in noninvasive diagnosis of liver fibrosis[J/CD]. Chin J Liver Dis (Electronic Version), 2021, 13(4): 9-13. DOI: 10.3969/j.issn.1674-7380.2021.04.003.

    程丹颖, 李贲, 纪世博, 等. 瞬时弹性成像技术在肝纤维化无创诊断中的应用[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(4): 9-13. DOI: 10.3969/j.issn.1674-7380.2021.04.003.
    [11]
    OBMANN VC, MARX C, BERZIGOTTI A, et al. Liver MRI susceptibility-weighted imaging (SWI) compared to T2* mapping in the presence of steatosis and fibrosis[J]. Eur J Radiol, 2019, 118: 66-74. DOI: 10.1016/j.ejrad.2019.07.001.
    [12]
    JIANG JZ, DENG LB, RUAN JY, et al. Value of susceptibility weighted imaging in hepatic fibrosis staging by using MR in a rabbit model[J]. J Chin Med, 2016, 96(17): 1371-1376. DOI: 10.3760/cma.j.issn.0376-2491.2016.17.015

    江锦赵, 邓灵波, 阮继银, 等. 磁敏感加权成像在兔肝脏纤维化模型分期中的诊断价值[J]. 中华医学杂志, 2016, 96(17): 1371-1376. DOI: 10.3760/cma.j.issn.0376-2491.2016.17.015.
    [13]
    GANDON Y, OLIVIÉ D, GUYADER D, et al. Non-invasive assessment of hepatic iron stores by MRI[J]. Lancet, 2004, 363(9406): 357-362. DOI: 10.1016/S0140-6736(04)15436-6.
    [14]
    BALASSY C, FEIER D, PECK-RADOSAVLJEVIC M, et al. Susceptibility-weighted MR imaging in the grading of liver fibrosis: a feasibility study[J]. Radiology, 2014, 270(1): 149-158. DOI: 10.1148/radiol.13122440.
    [15]
    SHI DD, GUO R, LIU YH, et al. The value of gadoxetate disodium enhanced MRI in the quantitative assessment of liver fibrosis[J]. Chin J Radio, 2022, 56(3): 273-278. DOI: 10.3760/cma.j.cn112149-20210316-00236.

    师丹丹, 郭然, 刘月华, 等. 钆塞酸二钠增强MRI定量评估肝纤维化的价值[J]. 中华放射学杂志, 2022, 56(3): 273-278. DOI: 10.3760/cma.j.cn112149-20210316-00236.
    [16]
    LI GP, ZHANG HX, ZHANG L, et al. HA, Ⅳ-C, APRI and Fib-4 for diagnosis of liver fibrosis effect after hepatitis B[J]. J Clin Exp Med, 2021, 20(13): 1385-1388. https://www.cnki.com.cn/Article/CJFDTOTAL-SYLC202113011.htm

    李广平, 张红心, 张蕾, 等. 透明质酸、Ⅳ型胶原、APRI及纤维蛋白原-4对乙型肝炎后肝纤维化的诊断价值[J]. 临床和实验医学杂志, 2021, 20(13): 1385-1388. https://www.cnki.com.cn/Article/CJFDTOTAL-SYLC202113011.htm
    [17]
    YANG XZ, GEN AW, XIAN JC, et al. Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis[J]. Eur Rev Med Pharmacol Sci, 2018, 22(2): 479-485. DOI: 10.26355/eurrev_201801_14198.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(3)

    Article Metrics

    Article views (300) PDF downloads(81) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return